ZA9710292B - Atherosclerosis treatment - Google Patents

Atherosclerosis treatment

Info

Publication number
ZA9710292B
ZA9710292B ZA9710292A ZA9710292A ZA9710292B ZA 9710292 B ZA9710292 B ZA 9710292B ZA 9710292 A ZA9710292 A ZA 9710292A ZA 9710292 A ZA9710292 A ZA 9710292A ZA 9710292 B ZA9710292 B ZA 9710292B
Authority
ZA
South Africa
Prior art keywords
atherosclerosis treatment
atherosclerosis
treatment
medicament
chem
Prior art date
Application number
ZA9710292A
Other languages
English (en)
Inventor
Robert Joseph Aiello
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA9710292B publication Critical patent/ZA9710292B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47J—KITCHEN EQUIPMENT; COFFEE MILLS; SPICE MILLS; APPARATUS FOR MAKING BEVERAGES
    • A47J47/00—Kitchen containers, stands or the like, not provided for in other groups of this subclass; Cutting-boards, e.g. for bread
    • A47J47/02—Closed containers for foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
ZA9710292A 1996-11-15 1997-11-14 Atherosclerosis treatment ZA9710292B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3127396P 1996-11-15 1996-11-15

Publications (1)

Publication Number Publication Date
ZA9710292B true ZA9710292B (en) 1999-05-17

Family

ID=21858549

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9710292A ZA9710292B (en) 1996-11-15 1997-11-14 Atherosclerosis treatment

Country Status (17)

Country Link
US (1) US6034102A (de)
EP (1) EP0842661B1 (de)
JP (1) JP3287793B2 (de)
KR (1) KR100367793B1 (de)
AT (1) ATE202702T1 (de)
AU (1) AU740378B2 (de)
CA (1) CA2221114C (de)
DE (1) DE69705480T2 (de)
DK (1) DK0842661T3 (de)
ES (1) ES2158452T3 (de)
GR (1) GR3036455T3 (de)
HU (1) HU223942B1 (de)
IL (1) IL122123A (de)
MY (1) MY114586A (de)
NZ (1) NZ329174A (de)
PT (1) PT842661E (de)
ZA (1) ZA9710292B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
CA2367895A1 (en) 1999-03-17 2000-09-21 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
CO5170459A1 (es) * 1999-06-01 2002-06-27 Pfizer Prod Inc Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
EP1113007A1 (de) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisochinolin-Verbindungen zur Verwendung als Östrogen-Agonisten/-Antagonisten
PT1229909E (pt) * 2000-06-01 2004-04-30 Watson Pharmaceiticals Inc Entrega transdermica de lasofoxifeno
AU2001288682A1 (en) 2000-08-30 2002-03-13 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
TWI303990B (en) * 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
WO2002041827A2 (en) 2000-11-24 2002-05-30 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
WO2002047723A1 (fr) * 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicamenteuses presentant une meilleure hydrosolubilite
WO2002062296A2 (en) * 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US6821998B2 (en) * 2001-08-30 2004-11-23 Chemocentryx, Inc. Arylamines as inhibitors of chemokine binding to US28
CA2589746A1 (en) * 2004-12-08 2006-06-15 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
AU2014241162A1 (en) 2013-03-27 2015-10-22 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
DE4320898A1 (de) * 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Also Published As

Publication number Publication date
KR100367793B1 (ko) 2003-04-21
JPH10147527A (ja) 1998-06-02
ATE202702T1 (de) 2001-07-15
KR19980042432A (ko) 1998-08-17
EP0842661A3 (de) 1998-09-02
DK0842661T3 (da) 2001-09-24
AU4523797A (en) 1998-05-21
MY114586A (en) 2002-11-30
AU740378B2 (en) 2001-11-01
CA2221114A1 (en) 1998-05-15
US6034102A (en) 2000-03-07
DE69705480T2 (de) 2001-10-31
EP0842661B1 (de) 2001-07-04
CA2221114C (en) 2003-10-28
EP0842661A2 (de) 1998-05-20
HU9702040D0 (en) 1998-01-28
HU223942B1 (hu) 2005-03-29
IL122123A0 (en) 1998-04-05
NZ329174A (en) 2000-10-27
IL122123A (en) 2001-07-24
DE69705480D1 (de) 2001-08-09
JP3287793B2 (ja) 2002-06-04
HUP9702040A1 (hu) 2000-11-28
GR3036455T3 (en) 2001-11-30
PT842661E (pt) 2001-10-30
ES2158452T3 (es) 2001-09-01

Similar Documents

Publication Publication Date Title
GR3036455T3 (en) Atherosclerosis treatment
SG47520A1 (en) New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
TW269678B (de)
DE69319976D1 (de) 7-Substituierte-9-substituierte Glycylamido-6-Demethyl-6-Deoxytetracycline
TW279858B (de)
FI943142A0 (fi) Amidi- ja ureajohdannaiset, joilla on veren korkeita kolesteroliarvoja vastustava vaikutus, niiden valmistus ja terapeuttiset käytöt
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
ATE263771T1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
HU9502270D0 (en) Novel pyrrolocarbazoles
ID23053A (id) Karboksamida yang digunakan sebagai agonis 5-ht <if>
ATE143023T1 (de) Chirale 1,5-diiodo-2-methoxy oder benzyloxy zwischenprodukte
HUT71512A (en) N-(3-chlorophenyl)-piperazine derivatives for producing alkyl-trazodon derivatives and process for producing them
FI954213A (fi) Kasvainten vastaisia koostumuksia ja hoitomenetelmiä
TW275629B (de)
EP0443474A3 (en) 1-phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents
GR3020597T3 (en) Phospholipids for the treatment of multiple sclerosis